Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Official title

Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study

Study identification

NCT ID

NCT05929768

Recruitment status

Recruiting

Study type

Interventional

Phase

Phase 3

Lead sponsor

SWOG Cancer Research Network

Network

Enrollment

2,400 participants

Conditions and interventions

Eligibility (public fields only)

Age range

18 Years and older

Sex

All

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Sep 14, 2023

Primary completion

Mar 30, 2033

Completion

Mar 31, 2033

Last update posted

Nov 4, 2025

2023 – 2033

United States locations

U.S. sites

955

U.S. states

48

U.S. cities

657

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.